Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO)
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
Expert recommendations on the usage of non-vitamin K antagonist oral anticoagulants (NOACs) from India: Current perspective and future direction
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study
F Shaikh, R Wynne, R L. Castelino… - … Advances in Drug …, 2024 - journals.sagepub.com
Background: Atrial fibrillation (AF) and obesity are common conditions globally; yet, there
remains suboptimal pharmacological management contributing to high rates of …
remains suboptimal pharmacological management contributing to high rates of …
[HTML][HTML] Direct oral anticoagulation and severe obesity–One size fits all?
Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
Practices, beliefs, and attitudes of clinicians in prescribing direct oral anticoagulants for obese adults with atrial fibrillation: a qualitative study
F Shaikh, R Wynne, RL Castelino, SC Inglis… - International Journal of …, 2023 - Springer
Background Atrial fibrillation (AF) and obesity affect over 60 and 650 million people,
respectively. Aim This study aimed to explore clinician practices, beliefs, and attitudes …
respectively. Aim This study aimed to explore clinician practices, beliefs, and attitudes …
Obesity as a risk factor in atrial fibrillation and heart failure
Objectives The aim of this article is to provide an insight into the role of obesity as a risk
factor, and as a potential etiologic agent of atrial fibrillation (AF) and heart failure (HF) …
factor, and as a potential etiologic agent of atrial fibrillation (AF) and heart failure (HF) …
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics
S Agewall - European Heart Journal-Cardiovascular …, 2024 - academic.oup.com
In a retrospective study, Dr Liu et al. from Hong Kong, compared the effects between sodium-
glucose cotransporter-2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) on …
glucose cotransporter-2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) on …
Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity
BL Erstad, JF Barletta - Annals of Pharmacotherapy, 2023 - journals.sagepub.com
Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …
[PDF][PDF] Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
BSPPH Kumar, S George, SMVGGN Gupta, K Makineni… - 2022 - academia.edu
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …